StockData
Xenetic Biosciences, Inc. logo

Xenetic Biosciences, Inc. (XBIO) stock

XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3067% below fair value
$1.61+0.12 (+8.05%)

Close on Nov 17, 2026Market cap $3.77MP/E –Yield –

Xenetic Biosciences gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2013 it was 100.0%, against 84.7% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2013Dec 31, 2013100.0%+15.3
FY2012Dec 31, 201284.7%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2017Sep 30, 2017-14.2%–

More Xenetic Biosciences figures

See a number that looks wrong?